SpaceX Buys Cursor for $60 Billion and Trump Signs an Iran Deal at Versailles

Days after pulling off the largest IPO in history, SpaceX went shopping. On June 16 it agreed to acquire Anysphere, the company behind the AI coding tool Cursor, in an all-stock deal valuing the target at about $60 billion. It is, by wide consensus, the largest acquisition of a venture-backed startup ever, and it is roughly double the $29.3 billion private valuation Cursor reached only late last year.

Cursor is one of the breakout successes of the AI era. Its coding agent lets developers write, search, and edit code using plain-language instructions, and it had surged to about $2 billion in annual recurring revenue by early 2026, with more than 50,000 enterprise clients and developers at roughly two-thirds of the Fortune 500 using it. That kind of enterprise penetration is exactly what SpaceX is buying.

The logic runs through xAI, Elon Musk's AI lab, which SpaceX absorbed in February 2026 at a $250 billion valuation, as part of a record $1.25 trillion combination that folded frontier-model ambitions into the same entity. Acquiring Cursor hands that combined AI division an instant foothold in enterprise software and a proven distribution channel, a way to catch the leading labs by buying reach rather than building it from scratch. The deal is structured as all stock, with each Cursor share converting into SpaceX Class A stock at an exchange ratio set by the volume-weighted average price of SpaceX shares over the seven trading days before closing, which is expected in the third quarter of 2026 pending regulatory approval.

The structure is its own lesson. A company that went public only days earlier is already using its freshly minted, highly valued stock as acquisition currency, the classic playbook of a richly valued public company buying growth with paper rather than cash. It also concentrates yet more of the AI landscape inside a single Musk-controlled entity.

For dealmakers, the transaction is a marquee credential and a signal. The AI land grab is no longer just about funding rounds; it is now playing out through multibillion-dollar M&A at valuations that would have been unthinkable for a four-year-old company in any prior cycle. When the year's hottest new listing immediately spends $60 billion of its stock on an AI startup, it tells every board and banker that the race for AI capability has moved into the M&A market, and that the price of admission is steep.

The week's defining geopolitical event was a signature in a palace, and the backlash that followed it. On June 17, President Donald Trump signed a preliminary peace agreement with Iran at the Palace of Versailles, during a G7 dinner hosted by French President Emmanuel Macron. Iranian President Masoud Pezeshkian signed as well, with Pakistan mediating, and the document was inked two days ahead of schedule. It commits both sides to halt a war that began in late February, reopens the Strait of Hormuz to shipping, and eases US sanctions, with a 60-day clock to negotiate a permanent treaty and a reconstruction fund reported at $300 billion.

The terms are what lit the fuse. Under the 14-point memorandum, the US agreed to terminate sanctions, unfreeze Iranian assets, and lift its naval blockade, while Iran merely reaffirmed it would not build nuclear weapons, with the fate of its enriched-uranium stockpile left to a mechanism still to be 'mutually agreed.' To critics, that traded concrete American concessions for a vague Iranian promise.

The reaction was scathing, above all in Israel. Finance minister Bezalel Smotrich called the accord 'a bad deal for Israel and the entire free world,' and national security minister Itamar Ben-Gvir said Trump's agreement did not bind Israel and that the country should defy the ceasefire, with Israeli officials signaling they would not feel bound by its terms. In Washington the criticism crossed party lines. Senate Democratic leader Chuck Schumer demanded that the administration release the deal's details and brief Congress, questioning what the US had actually gained, while the memorandum's pledge to help fund a $300 billion reconstruction plan for Iran became a flashpoint that drew fire from Republicans and even some of Trump's own supporters. Vice President JD Vance was left publicly defending the deal and rebuking its critics.

The mechanics are contested, too. Washington says the Strait of Hormuz will stay toll-free indefinitely, but Iranian negotiators have signaled that once the 60-day interim period ends, Tehran intends to charge transit fees, citing maritime sovereignty. A first round of technical talks set for Friday in Switzerland was initially called off after Iran demanded that Israel halt its Lebanon offensive, before resuming over the weekend. Analysts also noted that Trump has proclaimed an Iran deal all but done dozens of times, and markets have learned to treat each such claim with caution.

Markets took the optimistic side but kept one eye on the exits. Oil, which had spiked above $120 a barrel during the war as Hormuz was shut, settled back toward $80 for Brent crude, roughly a third below the conflict peak. Yet the canceled Friday talks and the chorus of criticism tempered the relief, and traders know the physical recovery will take months as a backlog of stranded tankers and shut-in production comes back online.

For finance, the episode is a vivid lesson in how a single geopolitical event reprices the whole board, and how fragile that repricing can be. A double-digit swing in crude feeds straight into inflation, central-bank decisions, and the cost of financing energy deals. The war-risk premium has eased, but a deal this contested, rejected by a key US ally and attacked at home, is exactly the kind markets price as reversible. The relief is real; whether it lasts is the open question.

On June 15, Fox Corporation agreed to acquire Roku in a cash-and-stock deal valuing the streaming company at about $22 billion. Roku shareholders will receive $160.00 a share, split as $96.00 in cash and 0.9693 shares of Fox Class A common stock for each Roku share, in a transaction unanimously approved by both boards. When it closes, expected in the first half of 2027 subject to shareholder and regulatory approval, existing Fox holders would own about 73% of the combined company and Roku holders about 27%.

The strategic rationale is a pivot. Fox, led by chairman and chief executive Lachlan Murdoch, has been one of the more focused legacy media companies, leaning on live news and sports plus its free streaming service Tubi. Roku brings the missing piece: a streaming operating system and ad platform that reaches nearly half of US broadband households, along with the data and distribution that come with it. Together the two would rank among the largest US players by share of television viewing, turning Fox from a network owner into a streaming distributor.

The consideration mix is worth dwelling on, because it is a clean example of how a cash-and-stock deal works. The $96.00 cash gives Roku holders certainty, while the 0.9693 Fox shares hand them a stake in the combined company, so they share in both the upside and the integration risk rather than simply cashing out. Fox is also leaning on synergy math to justify the price, targeting roughly $400 million in run-rate cost synergies and projecting that the deal turns accretive to free cash flow per share by the second full year after closing.

That synergy and accretion framing is the heart of the pitch, and the usual caution applies: the value is not in the $22 billion headline but in whether the two businesses can actually be stitched together to deliver the promised savings and growth. Integration, not the price, will decide it.

The deal also reads as a marker for media consolidation. As linear television keeps fading, an old-media incumbent is paying up to own a streaming distribution layer rather than be disintermediated by one. It will test the appetite of antitrust regulators, who have taken a lighter-touch stance in 2026 but still scrutinize media combinations of this scale.

Nuvei, the payments-technology company, agreed on June 15 to acquire Payoneer for $7.40 a share in cash, valuing Payoneer at about $2.75 billion in equity. The deal pairs two cross-border payments businesses, but the more revealing angle is who is really behind it.

Nuvei is owned by Advent International, the private equity firm that took it private in 2024 in a deal worth roughly $6.3 billion. This is Nuvei's first significant acquisition since leaving the public markets, and it is a textbook example of the sponsor-backed playbook: a private-equity-owned platform using its owner's capital and balance sheet to pursue bolt-on M&A away from the scrutiny of public shareholders. Buy a platform, take it private, then build it up through add-ons, which are frequently funded with private credit, is one of the defining strategies of modern private equity.

The strategic fit is in the plumbing of global commerce. Nuvei brings merchant payment processing, while Payoneer contributes a cross-border payout network, multi-currency accounts, and regulatory licenses across more than 150 countries, aimed at small businesses and online marketplaces that move money internationally. Together they form a larger end-to-end platform spanning the money coming in and the money going out.

There is a neat round-trip in the story, too. Payoneer itself went public through a SPAC merger in 2021, at the height of that boom, and is now being taken private again barely five years later. It is a small monument to how many companies that rushed to list in 2021 have since concluded that the public markets were not the right home, and have found their way back into private hands, often a sponsor's.

For anyone learning the private-markets game, the deal is a clean illustration of buy-and-build in action. The value case does not rest on a takeover premium or a flashy growth story; it rests on whether Advent and Nuvei can integrate Payoneer, cut overlapping costs, and cross-sell across a combined customer base, the same execution-driven logic that underpins most sponsor roll-ups. It is also one more public company quietly leaving the exchange, a reminder that even in a year of blockbuster listings, the flow runs both ways.

A week after SpaceX's record debut, the IPO market sent a quieter but telling signal. On June 17, cardiovascular biotech Kardigan priced an upsized initial public offering at $16.00 a share, the top of its range, raising about $400 million in gross proceeds, and its stock began trading on the Nasdaq the next day under the ticker KARD. The company had initially targeted around $350 million, then upsized as demand firmed.

Kardigan is a classic pre-profit biotech. It is a clinical-stage company built around three cardiovascular drug programs, Danicamtiv, Ataciguat, and Tonlamarsen, that are still in mid-to-late-stage trials. It has no product revenue and reported a net loss of roughly $230 million for the twelve months ended March 31, 2026. Investors are buying a pipeline and a probability of approval, not earnings, which is exactly how loss-making, science-stage companies get valued.

What makes the listing notable is breadth. SpaceX proved the market would swallow a trillion-dollar mega-IPO, but a single giant deal does not tell you whether the window is truly open. A $400 million biotech pricing at the top of its range, and extending a genuine streak of sizable biotech listings, says the recovery has spread well beyond a handful of marquee names into the kind of mid-cap, sector-specific issuance that makes a real IPO market.

For the banks, that breadth is the story. Equity capital markets desks need a steady calendar of healthcare, industrial, and consumer deals, not just one rocket, to put their teams and balance sheets to work. Biotech in particular had been frozen for stretches of the prior few years, so its return is a meaningful sign that risk appetite has broadened.

It also fits the texture of the 2026 market. Even with financing not getting much cheaper, investors are still willing to fund a company that loses hundreds of millions a year on the promise of future cash flows. That appetite for long-duration growth stories, set against a cautious rate backdrop, is what the year's market looks like, and Kardigan is a small, clean example of it.

On June 16, Olin Corporation and Huntsman Corporation agreed to combine in an all-stock merger of equals, creating a North American chemicals leader with roughly $12.5 billion in combined 2025 revenue. The new company will be renamed OlinHuntsman, with Ken Lane as chief executive and Peter Huntsman as non-executive chairman, and the deal is expected to close in the first half of 2027 subject to shareholder and regulatory approvals.

The terms reflect the merger-of-equals framing. Huntsman shareholders will receive 0.5476 Olin shares for each Huntsman share, leaving Olin holders with about 54.5% of the combined company and Huntsman holders about 45.5%. The two sides have identified more than $400 million in annual cost synergies, which is where the value of the combination is meant to come from.

A merger of equals is worth understanding as a structure, because it differs from a typical takeover. Rather than one company paying a premium to buy another for cash, two businesses of comparable size combine their stock, share governance, and aim to create value through scale and synergies instead of through a control premium. There is no big cash payout and no single acquirer; both sets of shareholders ride the combined company, which is why the synergy and integration plan, not a headline price, is the whole story.

The strategic logic is consolidation in a soft market. The chemicals cycle has been weak, with sluggish demand pressuring producers of chlor-alkali, epoxy, and polyurethane products. Combining lets the two cut overlapping costs, gain scale to weather the cyclicality, and compete more effectively against larger global rivals. It is a defensive, efficiency-driven deal of the kind that tends to appear when organic growth is hard to find.

For the industry, OlinHuntsman is a tidy example of how mid-cap players use structure to grow when the cycle is against them. An all-stock merger of equals sidesteps the need to raise expensive financing in a higher-rate environment and pushes the entire bet onto execution. Whether the combination delivers will come down to integration and the promised $400 million of savings, not the size of the company it creates.